Physician profile
Ivan M Jonas
NPI 1265438410
$4,805.85
in general payments reported to CMS, 2019-2025
41 companies · $65.96 in 2025
The $65.96 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $103 · 2021: $770 · 2022: $513 · 2023: $1,171 · 2024: $1,336 · 2025: $65.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $848.42 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $476.54 | 2019-2024 | |
| Pfizer INC. | $347.01 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $236.85 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $231.72 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $216.58 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $215.24 | 2019-2024 | Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $195.52 | 2022 | |
| Lilly USA, LLC | $180.78 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $162.67 | 2019-2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $147.41 | 2023-2024 | |
| Madrigal Pharmaceuticals | $140.15 | 2024 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $137.94 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $136.24 | 2019-2023 | Ocaliva |
| Idorsia Pharmaceuticals US INC | $134.95 | 2023 | Quviviq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Jonas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.